A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05514873` - An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors	Phase 3
Completed	`NCT04124965` - A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT04833894` - Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis	Phase 2/Phase 3
Active, not recruiting	`NCT04963270` - A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis	Phase 3
Active, not recruiting	`NCT02950155` - A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis	Phase 3
Completed	`NCT03315130` - Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis	Phase 2
Recruiting	`NCT05556096` - Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Phase 3
Not yet recruiting	`NCT06392386` - A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis	Phase 3
Not yet recruiting	`NCT06149559` - A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis	Phase 2/Phase 3
Not yet recruiting	`NCT06193889` - A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis	Phase 2
Completed	`NCT03920293` - Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis	Phase 3
Completed	`NCT03770403` - A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.	Phase 3
Not yet recruiting	`NCT06447597` - A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.	Phase 2/Phase 3
Completed	`NCT03971422` - A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT05403541` - Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT05644561` - Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)	Phase 3
Not yet recruiting	`NCT06456580` - A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)	Phase 3
Not yet recruiting	`NCT06463587` - Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)	Phase 3
Recruiting	`NCT06055959` - A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis	Phase 2/Phase 3
Completed	`NCT00515450` - Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis	Phase 3

NCT number	NCT05681715
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 3
Start date	April 17, 2023
Completion date	April 23, 2024

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms